Familial adenomatous polyposis (FAP) is caused by mutations in the APC gene and 2 different, or biallelic mutations, in the MUTYH gene. However, not all patients with colorectal polyposis are found to ...
Familial adenomatous polyposis is caused by abnormalities in the APC gene. The Food and Drug Administration (FDA) has granted Fast Track designation to REC-4881 for the treatment of familial ...
Encapsulated rapamycin is expected to prevent disease progression by inhibiting mTOR, a protein kinase that has been shown to be overexpressed in FAP polyps. The Food and Drug Administration (FDA) has ...
Please provide your email address to receive an email when new articles are posted on . For patients with familial adenomatous polyposis, incidence of disease progression was not significantly lower ...
Recursion, a clinical-stage TechBio company, is set to present preliminary data from its Phase 1b/2 clinical trial, TUPELO, at the 2025 Digestive Disease Week (DDW) meeting on May 4, 2025, in San ...
Identification of High-Performing Safety Net Hospitals for Radical Cystectomy: Implications for National Cancer Institute Cancer Center Partnership Familial adenomatous polyposis (FAP) is an autosomal ...
Biodexa Pharmaceuticals PLC announced the activation of its first clinical study site for the Phase 3 Serenta trial, which aims to evaluate the efficacy and safety of eRapa in treating familial ...
Familial adenomatous polyposis coli (FAP) has been shown to be associated with germline mutations of the adenomatous polyposis gene (APC) on chromosome 5. Extra-colonic manifestations also occur in ...
Researchers from Tel Aviv University and Tel Aviv Sourasky Medical Center (Ichilov Hospital) have developed an innovative drug treatment for familial adenomatous polyposis (FAP), a rare, inherited ...
Researchers have developed an innovative drug treatment for familial adenomatous polyposis (FAP), a rare, inherited condition that affects adolescents and young adults and often leads to colorectal ...
Biodexa Pharmaceuticals PLC (BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is pleased to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results